Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases

This review summarises the available evidence of recent CV outcomes trials of SGLT2 inhibitors, focusing particularly on the application of these agents across various CV diseases, including evidence to support increased utilisation of these drugs.

Source:

Heart